U.S. Mortgage REITs Stock News

Huntington Bancshares (NasdaqGS:HBAN) has closed its merger with Cadence Bank. The deal expands Huntington's geographic footprint, including leading deposit market share in Mississippi and a larger presence in Texas. Three former Cadence directors have joined Huntington's board, changing the company's governance mix. For you as an investor, this merger reshapes Huntington into a broader regional banking platform with a stronger position across key Southern markets. The combined business now...

In late January and early February 2026, Bio-Techne launched its Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix designed to improve reproducibility and scalability in 3D stem cell and organoid research, alongside new ultra-sensitive Simple Plex assays on its Ella platform for early neurodegenerative biomarker detection. The Cultrex Synthetic Hydrogel directly targets regulatory- aligned workflows and new approach methodologies by reducing biological variability...

IDEXX Laboratories (IDXX) has just wrapped up FY 2025 with fourth quarter revenue of US$1,090.6 million and basic EPS of US$3.11, alongside trailing twelve month revenue of US$4.3 billion and EPS of US$13.17 that frame the latest print against a fuller year of performance. Over recent quarters the company has seen revenue move from US$954.3 million in Q4 2024 to just above US$1.1 billion in Q2 and Q3 2025, while quarterly EPS stepped from US$2.64 to a range between roughly US$3.0 and US$3.66,...

Napco Security Technologies (NSSC) just posted Q2 2026 results with revenue of US$48.2 million and basic EPS of US$0.38, alongside net income of US$13.5 million, putting fresh numbers on the table for investors tracking its profitability. The company has seen quarterly revenue move from US$42.9 million in Q2 2025 to US$48.2 million in Q2 2026, while basic EPS shifted from US$0.29 to US$0.38 over the same span. Trailing twelve month EPS stands at US$1.33 and net income at US$47.4 million,...

Red Cat Holdings (RCAT) is back in focus after an Asia Pacific ally selected its Black Widow small unmanned aerial system in a competitive tender, the second regional order in recent months for military use. See our latest analysis for Red Cat Holdings. The latest order lands against a backdrop of strong recent momentum, with a 48.8% 1 month share price return and a 54.5% 1 year total shareholder return, while the 3 year total shareholder return is roughly 9x. If this drone contract has you...

With no single headline event setting the tone today, Winnebago Industries (WGO) is drawing attention as investors weigh its recent share performance, current valuation signals, and the backdrop of its recreational vehicle and marine businesses. See our latest analysis for Winnebago Industries. Recent trading has been relatively steady, with a 30 day share price return of 12.83% and a 90 day gain of 27.54% from the current US$46.08 level. The 1 year total shareholder return of 3.12% contrasts...

If you are wondering whether Cboe Global Markets is priced attractively today, it helps to step back and separate share price excitement from underlying value. The stock last closed at US$263.92, with a 2.3% decline over the past 7 days, a 6.4% return over the past month and year to date, and a 27.4% return over the past year, which may influence how you think about its future risk and reward. Recent attention on Cboe Global Markets has centered on its role as a major exchange operator and...

Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 study, showing that once-daily ZORYVE cream 0.05% was well tolerated and improved atopic dermatitis in infants aged 3 months to under 24 months, with low rates of mostly mild to moderate adverse events. The findings extend ZORYVE’s safety and efficacy profile into even younger pediatric patients, potentially broadening its role as a non-steroidal option in a population where steroid concerns...

In late January and early February 2026, GE Vernova reported stronger fourth-quarter and full-year 2025 results, raised its multi-year outlook, launched a fixed-rate senior unsecured notes offering, and closed the purchase of the remaining 50% stake in transformer maker Prolec GE to expand its Electrification segment. Together with a completed US$3.34 billion share buyback and growing orders and backlog, these moves tighten GE Vernova’s capital structure while deepening its role across power...

CRISPR Therapeutics recently outlined its 2026 milestones and priorities, including continued global rollout of Casgevy, planned regulatory filings for younger patients, and advancement of several gene-editing programs across cardiovascular, autoimmune, and oncology indications. At the same time, ARK Investment Management has been adding to its CRISPR Therapeutics position, underscoring institutional interest in the company’s CRISPR/Cas9 platform as it moves beyond rare blood disorders into...

On January 20, Guggenheim and JonesResearch initiated coverage of AtaiBeckley, highlighting the company’s role in next-generation psychiatry following its merger with Beckley Psytech and full ownership of lead asset BPL-003 for treatment-resistant depression. The merger-backed consolidation of BPL-003 under AtaiBeckley underscores how control of a single late-stage psychiatry asset can reshape a specialist pipeline’s profile. Next, we assess how this enhanced control of BPL-003 influences...

Recent share moves and where Exxon Mobil (XOM) stands now Exxon Mobil (XOM) has drawn fresh attention after a recent run in its share price, with the stock up around 13% over the past month and about 21% in the past 3 months. See our latest analysis for Exxon Mobil. That recent strength comes after a choppy year, with a 1 year total shareholder return of 33.98% supported by dividends and a 5 year total shareholder return of about 3x, even though the latest 1 day share price return of a 2.12%...

Lucid Group's Lucid Air Grand Touring recorded the longest range result at the 2026 Norges Automobil Forbund Winter Test. The company plans to preview a new midsize vehicle and present a broader roadmap at its upcoming Investor Day. Investor Day is expected to cover Lucid's future product pipeline, autonomy plans, and software development priorities. For investors watching NasdaqGS:LCID, this mix of product performance and roadmap detail comes at a time when premium EV makers are under...

How Tyson Foods' Latest Numbers Fit the Bigger Earnings Story Tyson Foods (TSN) has just reported its Q1 2026 results, with recent quarterly revenue ranging from about US$13.1b to US$13.9b and basic EPS between roughly US$0.02 and US$1.01, while trailing twelve month figures include total revenue of about US$54.4b and EPS of around US$1.33. Over the last few reported quarters, the company has seen revenue move from US$13.6b in Q1 2025 to US$13.9b in Q4 2025, with quarterly EPS shifting from...

Paychex recently expanded its Board of Directors to 11 members and appointed former Cintas CFO J. Michael Hansen as an independent director, assigning him to the Audit Committee with immediate effect. Hansen’s long financial career, including his experience at Cintas and prior board role at Paycor (now owned by Paychex), deepens the company’s governance and financial oversight bench. We’ll explore how this board appointment, alongside analyst concerns about growth and acquisition benefits,...

BeOne Medicines reported pivotal Phase 3 trial results in gastric cancer for its pipeline, confirming a key late stage clinical milestone. The company also received its first regulatory clearance for sonrotoclax, a next generation BCL2 inhibitor. These updates expand the medical and commercial potential of BeOne Medicines beyond previously disclosed information. For investors watching BeOne Medicines, ticker NasdaqGS:ONC, the news comes at a time when the stock has shown strong longer term...

Denali Therapeutics recently highlighted past and upcoming presentations of clinical and preclinical data for its Enzyme Transport Vehicle programs in rare lysosomal storage disorders, alongside an ongoing FDA Priority Review of tividenofusp alfa for Hunter syndrome with a decision expected by 5 April 2026. The FDA’s halt of a competing Hunter syndrome gene therapy trial has drawn attention to Denali’s ETV platform as a potential alternative approach for delivering enzyme replacement...

Why Honeywell’s latest quarter grabbed investor attention Honeywell International (HON) is back in focus after its fourth quarter beat on adjusted earnings, with double digit organic revenue growth, a record backlog above US$37b, and updated 2026 guidance that reinforced management’s profitability message. See our latest analysis for Honeywell International. The renewed interest around Honeywell’s earnings beat, record backlog and 2026 outlook has come alongside a 16.2% year to date share...

Broadcom (NasdaqGS:AVGO) is expanding its role in custom AI accelerators and ASIC design for major clients such as Google and OpenAI, supporting rapid growth in its AI semiconductor revenue. The company has recently emerged as a key partner in building AI infrastructure, with multiple analysts highlighting its position in AI custom-chip development. Broadcom also resolved a legal dispute with Fidelity related to VMware software licensing, removing a potential operational hurdle following the...

OpenText (NasdaqGS:OTEX) has appointed Ayman Antoun as Chief Executive Officer. The company has agreed to divest its Vertica business to concentrate on core cloud and AI offerings. These decisions were announced together, signaling a shift in leadership and portfolio focus. OpenText operates in enterprise information management, supplying software that helps large organizations manage content, security, and data across on-premises and cloud environments. The arrival of a new CEO with a...

Operational headwinds put John Wiley & Sons (WLY) under closer investor scrutiny Recent commentary on John Wiley & Sons (WLY) points to ongoing declines in sales and free cash flow margins, with weak demand projected over the next year and higher capital needs raising fresh questions about long term growth. See our latest analysis for John Wiley & Sons. Wiley's share price has climbed 6.41% over the past month but is still down 17.18% over the last 90 days, while its 1 year total shareholder...

Analyst caution meets resilient fundamentals at Zoetis Zoetis (ZTS) is back in focus after several Wall Street firms recently downgraded or tempered their views, highlighting an innovation air pocket even as the animal health group continues to show solid cash generation and dividend consistency. See our latest analysis for Zoetis. Recent rating changes and trimmed outlooks have coincided with a soft patch in Zoetis’ share price, with a 1 year total shareholder return of 26.28% decline and a...

Teledyne Technologies recently reported full-year 2025 results, with sales of US$6,115.4 million and net income of US$894.8 million, issued 2026 earnings guidance, completed a US$400 million buyback of 800,000 shares, announced a board retirement effective April 2026, and highlighted new defense and space imaging wins. Fresh contracts for Black Hornet 4 reconnaissance systems in Switzerland and GAVIA underwater vehicles in Sweden, alongside NASA’s BlackCAT mission deployment, underline...

Eli Lilly (NYSE:LLY) is committing $3.5 billion to build a new manufacturing facility in Pennsylvania focused on next generation weight loss medicines. The company has also entered multibillion-dollar collaborations with Repertoire Immune Medicines to pursue autoimmune treatments. A separate agreement with Seamless Therapeutics targets gene editing approaches for genetic hearing loss. Eli Lilly enters this phase of expansion with its shares at $1,044.13 and a 5-year return of 434.7%. The...